With the quiet period out of the way, a number of firms initiate coverage on recent IPO Enanta...

|About: Enanta Pharmaceuticals, Inc. (ENTA)|By:, SA News Editor

With the quiet period out of the way, a number of firms initiate coverage on recent IPO Enanta Pharmaceuticals (ENTA +2.6%) today; JPMorgan with an Overweight, and Lerrink Swann and Credit Suisse both with an Outperform (I, II). CSFB says that using conservative assumptions, the HCV market could reach $13B by 2020, which translates to a doubling of patients treated. Enanta develops drugs for the treatment of a number of various infectious diseases, with HCV being one of its key areas.